SWOT Analysis for Lyra Therapeutics Inc

Companies with 10% increase in share price over three months, with rising net profit growth
Rising Net Cash Flow and Cash from Operating activity
Relative Outperformance versus Industry over the Quarter (3 Months)
PEG lower than Industry PEG
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Increasing profits every quarter for the past 3 quarters
Stock with Low PE (PE < = 10)
Volume Shockers
Stocks Outperforming their Industry Price Change in the Quarter

Companies with High Debt
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years
Highest fall from 52 Week High
High volume, top losers
Top Losers
Low Piotroski Score : Companies with weak financials
Annual net profit declining for last 2 years
Book Value Per Share deteriorating for last 2 years
Weak performer : Stock lost more than 20% in 1 month
Weak Momentum: Price below Short, Medium and Long Term Averages
Companies Increasing Debt as per Annual Report
RSI indicating price weakness
Top Losers